Keywords
Intracytoplasmic sperm injection (ICSI)
human chorionic gonadotropin hormones (HCG)
gonadotropin-releasing hormone (GnRH)
reproductive
Dual trigger
Ovulation
Fertilization
Infertility
Date
- Submitted: Jul 1, 2025
- Published: Sep 2, 2025
How to Cite
Abstract
Background: Infertility remains a significant global health concern. Optimizing hormonal triggers, such as human chorionic gonadotropin (HCG) with or without gonadotropin-releasing hormone (GnRH) agonists, is crucial to enhance reproductive outcomes. We aim to evaluate and compare the reproductive success rates of dual trigger protocols (HCG + GnRH agonist) versus HCG alone in women undergoing assisted reproductive technologies (IVF/ICSI).
Methods: A systematic search was conducted in PubMed, Scopus, and Web of Science for studies published up to January 2025. Studies comparing reproductive outcomes in women undergoing IVF/ICSI who received either dual trigger (HCG + GnRH agonist) or HCG alone were included. Data were analyzed using RevMan version 5.4 and R Studio version 4.4.1. The primary outcome was the clinical pregnancy rate. Secondary outcomes included live birth rate, fertilization rate, and embryo quality metrics.
Results: Seventeen studies with a total of 2,239 women were included: 1,118 in the dual trigger group and1,121in the HCG onlygroup.Thedualtriggergroupshowedsignificantlybetteroutcomesinterms of total oocytes retrieved, fertilized oocytes, follicles >15mm on trigger day, viable embryos, two pronuclei (2PN) formation, clinical pregnancy, biochemical pregnancy, live birth rate, good quality embryos, and fertilization rate.
Conclusions Dual triggering with HCG and GnRH agonist appears to significantly enhance reproductive outcomes compared to HCG alone in women undergoing IVF or ICSI. These findings support the broader adoption of dual trigger protocols in assisted reproductive practice.
References
1. Casper RF. Basic understanding of gonadotropin-releasing hormone-agonist triggering. Fertil Steril. 2015: 867 [PMID: 25712575, https://doi.org/10.1016/j.fertnstert.2014.12.129]
2. Farouk D, Hawas HM, Shaban MM, Mekhimer MI, Sheeba M, Nabil M. The administration of GnRH and HCG: double trigger vs HCG alone for follicular oocyte maturation in poor IVF responders—a randomized controlled trial. Middle East Fertility Society Journal. 2024: https://doi.org/10.1186/s43043-024-00211-8]
3. Devroey P, Van Steirteghem A. A review of ten years experience of ICSI. Hum Reprod Update. 2004: 19 [PMID: 15005461, https://doi.org/10.1093/humupd/dmh004]
4. O'Neill CL, Chow S, Rosenwaks Z, Palermo GD. Development of ICSI. Reproduction. 2018: F51 [PMID: 29636404, https://doi.org/10.1530/REP-18-0011]
5. Chang EM, Song HS, Lee DR, Lee WS, Yoon TK. In vitro maturation of human oocytes: Its role in infertility treatment and new possibilities. Clin Exp Reprod Med. 2014: 41 [PMID: 25045627, https://doi.org/10.5653/cerm.2014.41.2.41]
6. Ludwig M, Doody KJ, Doody KM. Use of recombinant human chorionic gonadotropin in ovulation induction. Fertil Steril. 2003: 1051 [PMID: 12738494, https://doi.org/10.1016/s0015-0282(03)00173-0]
7. Humaidan P, Alsbjerg B. GnRHa trigger for final oocyte maturation: is HCG trigger history? Reprod Biomed Online. 2014: 274 [PMID: 25043893, https://doi.org/10.1016/j.rbmo.2014.05.008]
8. Kol S, Humaidan P. LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango? Reprod Biomed Online. 2010: 590 [PMID: 20851052, https://doi.org/10.1016/j.rbmo.2010.06.031]
9. Alleyassin A, Ghasemi M, Aghahosseini M, Safdarian L, Sarvi F, Almasi-Hashiani A, Hosseinimousa S, Najafian A, Esmailzadeh A. Final oocyte maturation with a dual trigger compared to human chorionic gonadotropin trigger in antagonist co-treated cycles: A randomized clinical trial. Middle East Fertility Society Journal. 2018: 199 https://doi.org/10.1016/j.mefs.2018.01.001]
10. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990: 918 [PMID: 2119392, https://doi.org/10.1210/jcem-71-4-918]
11. Zhou C, Yang X, Wang Y, Xi J, Pan H, Wang M, Zhou Y, Xiao Y. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles. Hum Reprod. 2022: 1795 [PMID: 35595223, https://doi.org/10.1093/humrep/deac114]
12. Shapiro BS, Andersen CY. Major drawbacks and additional benefits of agonist trigger--not ovarian hyperstimulation syndrome related. Fertil Steril. 2015: 874 [PMID: 25707333, https://doi.org/10.1016/j.fertnstert.2015.01.035]
13. Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014: CD008046 [PMID: 25358904, https://doi.org/10.1002/14651858.CD008046.pub4]
14. Orvieto R. Triggering final follicular maturation: hCG, GnRH-agonist, or both, when and to whom? J Assist Reprod Genet. 2017: 1231 [PMID: 28656537, https://doi.org/10.1007/s10815-017-0982-7]
15. Zhu H, Zhao C, Pan Y, Zhou H, Jin X, Xu W, Zhang S. Dual Trigger for Final Follicular Maturation Improves Cumulative Live-Birth Rate in Ovarian Stimulation for Freeze-All In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles. Front Endocrinol (Lausanne). 2021: 708247 [PMID: 34349729, https://doi.org/10.3389/fendo.2021.708247]
16. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed). 2021: 790 [PMID: 34446261, https://doi.org/10.1016/j.rec.2021.07.010]
17. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019: l4898 [PMID: 31462531, https://doi.org/10.1136/bmj.l4898]
18. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016: 210 [PMID: 27919275, https://doi.org/10.1186/s13643-016-0384-4]
19. Sloth A, Kjolhede M, Sarmon KG, Knudsen UB. Effect of dual trigger on reproductive outcome in low responders: a systematic PRISMA review and meta-analysis. Gynecol Endocrinol. 2022: 213 [PMID: 34779694, https://doi.org/10.1080/09513590.2021.2000962]
20. Tehrani HG, Heidar N, Mardanian F, Mehrabian F, Naghshineh E, Motamedi N. Comparing the effect of three trigger methods (human HCG, combination of recombinant HCG with GnRH agonist, and double recombinant HCG) on the fertility outcome of patients with poor ovarian response in ovulation stimulation cycle (IVF/ICSI). Academic Journal of Health Sciences. 2023: 101 https://doi.org/10.3306/AJHS.2023.38.04.101]
21. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006: 173 [PMID: 16895629, https://doi.org/10.1016/s1472-6483(10)60612-8]
22. Yan MH, Sun ZG, Song JY. Dual trigger for final oocyte maturation in expected normal responders with a high immature oocyte rate: a randomized controlled trial. Front Med (Lausanne). 2023: 1254982 [PMID: 37869157, https://doi.org/10.3389/fmed.2023.1254982]
23. Maged AM, Ragab MA, Shohayeb A, Saber W, Ekladious S, Hussein EA, El-Mazny A, Hany A. Comparative study between single versus dual trigger for poor responders in GnRH-antagonist ICSI cycles: A randomized controlled study. Int J Gynaecol Obstet. 2021: 395 [PMID: 33011968, https://doi.org/10.1002/ijgo.13405]
24. Haas J, Bassil R, Samara N, Zilberberg E, Mehta C, Orvieto R, Casper RF. GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study. Hum Reprod. 2020: 1648 [PMID: 32563188, https://doi.org/10.1093/humrep/deaa107]
25. Ali SS, Elsenosy E, Sayed GH, Farghaly TA, Youssef AA, Badran E, Abbas AM, Abdelaleem AA. Dual trigger using recombinant HCG and gonadotropin-releasing hormone agonist improve oocyte maturity and embryo grading for normal responders in GnRH antagonist cycles: Randomized controlled trial. J Gynecol Obstet Hum Reprod. 2020: 101728 [PMID: 32173633, https://doi.org/10.1016/j.jogoh.2020.101728]
26. Abed WM, Selman MO. Outcome of GnRH antagonist ICSI cycles triggered by GnRH agonist plus Recombinant hCG versus triggered with Recombinant hCG alone in fresh autologous ICSI cycle. Iraqi Journal of Embryos and Infertility Researches. 2020: 119 https://doi.org/10.28969/IJEIR.v10.i1.r8]
27. Keskin M, Ecemis T, Atik A, Yegen P, Kalkan E, Yucel GS. Cycle outcomes of dual trigger (GnRH agonist+hCG) versus human chorionic gonadotropin trigger alone in POSEDION group 3-4 poor-responders and normo-responders: A prospective randomized study. J Gynecol Obstet Hum Reprod. 2023: 102633 [PMID: 37487959, https://doi.org/10.1016/j.jogoh.2023.102633]
28. Singh N, Kashyap A, Malhotra N, Mahey R, Vatsa R, Patel G. Comparison of the effects of two different trigger strategies - dual (hCG + Leuprolide) versus hCG trigger - in antagonist non-donor IVF: a randomized controlled trial. JBRA Assist Reprod. 2023: 467 [PMID: 37698459, https://doi.org/10.5935/1518-0557.20230040]
29. Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization. J Reprod Med. 2014: 63 [PMID: 24597289,
30. Kim SJ, Kim TH, Park JK, Eum JH, Lee WS, Lyu SW. Effect of a dual trigger on oocyte maturation in young women with decreased ovarian reserve for the purpose of elective oocyte cryopreservation. Clin Exp Reprod Med. 2020: 306 [PMID: 33227187, https://doi.org/10.5653/cerm.2020.03657]
31. Mahajan N, Sharma S, Arora PR, Gupta S, Rani K, Naidu P. Evaluation of dual trigger with gonadotropin-releasing hormone agonist and human chorionic gonadotropin in improving oocyte maturity rates: A prospective randomized study. J Hum Reprod Sci. 2016: 101 [PMID: 27382235, https://doi.org/10.4103/0974-1208.183506]
32. Decleer W, Osmanagaoglu K, Seynhave B, Kolibianakis S, Tarlatzis B, Devroey P. Comparison of hCG triggering versus hCG in combination with a GnRH agonist: a prospective randomized controlled trial. Facts Views Vis Obgyn. 2014: 203 [PMID: 25593695,
33. Eftekhar M, Farid Mojtahedi M, Miraj S, Omid M. Final follicular maturation by administration of GnRH agonist plus HCG versus HCG in normal responders in ART cycles: An RCT. International Journal of Reproductive BioMedicine. 2017: 429 https://doi.org/10.29252/ijrm.15.7.429]
34. Svenstrup L, Moller S, Fedder J, Pedersen DE, Erb K, Andersen CY, Humaidan P. Investigation of luteal HCG supplementation in GnRH-agonist-triggered fresh embryo transfer cycles: a randomized controlled trial. Reprod Biomed Online. 2024: 103415 [PMID: 38452605, https://doi.org/10.1016/j.rbmo.2023.103415]
35. Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O, Raziel A. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2008: 1087 [PMID: 18023439, https://doi.org/10.1016/j.fertnstert.2007.07.1316]
36. Mizrachi Y, Horowitz E, Farhi J, Levran D, Raziel A, Weissman A. Human chorionic gonadotropin serum levels following ovulation triggering and IVF cycle outcome. J Assist Reprod Genet. 2018: 891 [PMID: 29572693, https://doi.org/10.1007/s10815-018-1165-x]
37. Helmer A, Magaton I, Stalder O, Stute P, Surbek D, von Wolff M. Optimal Timing of Ovulation Triggering to Achieve Highest Success Rates in Natural Cycles-An Analysis Based on Follicle Size and Oestradiol Concentration in Natural Cycle IVF. Front Endocrinol (Lausanne). 2022: 855131 [PMID: 35692395, https://doi.org/10.3389/fendo.2022.855131]
38. Yuan M, Lv X, Yuan Y, Ju W, Song J, Pang C, Zhao S, Chen W, Lian F, Wu Z. Comparative analysis of hCG and dual-trigger protocols in IVF for advanced maternal age women: a single‑center retrospective cohort study based on propensity score matching. Arch Gynecol Obstet. 2025: [PMID: 40314810, https://doi.org/10.1007/s00404-025-08037-z]
39. Wu X, Yang L, Tang H, Luo S, Tang T, Ouyang M, Liu Z, Peng X, Pan X, Yu H. Safety and effectiveness of dual trigger (GnRH agonist + HCG) versus HCG alone in patients with high ovarian response. Am J Transl Res. 2024: 6668 [PMID: 39678590, https://doi.org/10.62347/QKPV5157]
40. Chen CH, Tzeng CR, Wang PH, Liu WM, Chang HY, Chen HH, Chen CH. Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis. Arch Gynecol Obstet. 2018: 17 [PMID: 29600322, https://doi.org/10.1007/s00404-018-4751-3]
41. Bourdon M, Peigné M, Solignac C, Darné B, Languille S, Pocate-Cheriet K, Santulli P. Gonadotropin-releasing hormone agonist (alone or combined with human chorionic gonadotropin) vs. human chorionic gonadotropin alone for ovulation triggering during controlled ovarian stimulation for in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis. F&S Reviews. 2021: 353 https://doi.org/10.1016/j.xfnr.2021.08.003]
42. Zhang Y, Guo X, Guo L, Chang HM, Shu J, Leung PCK. Outcomes comparison of IVF/ICSI among different trigger methods for final oocyte maturation: A systematic review and meta-analysis. FASEB J. 2021: e21696 [PMID: 34085322, https://doi.org/10.1096/fj.202100406R]
43. Hu KL, Wang S, Ye X, Zhang D, Hunt S. GnRH agonist and hCG (dual trigger) versus hCG trigger for follicular maturation: a systematic review and meta-analysis of randomized trials. Reprod Biol Endocrinol. 2021: 78 [PMID: 34059045, https://doi.org/10.1186/s12958-021-00766-5]
44. Lin M-H, Wu FS-Y, Hwu Y-M, Lee RK-K, Li R-S, Li S-H. Dual Trigger With Gonadotropin Releasing Hormone Agonist and Human Chorionic Gonadotropin Significantly Improves Live Birth Rate for Women With Diminished Ovarian Reserve. Obstetrical & Gynecological Survey. 2019: 534 https://doi.org/10.1097/ogx.0000000000000723]
45. Guner FC, Ozekinci M, Mendilcioglu, II, Kasabali Z. Reproductive Outcomes of Dual Trigger versus hCG Alone in Women Undergoing In Vitro Fertilization with Fresh Embryo Transfer Cycles. Obstet Gynecol Int. 2024: 9972437 [PMID: 39015476, https://doi.org/10.1155/2024/9972437]
46. Dong L, Lian F, Wu H, Xiang S, Li Y, Wei C, Yu X, Xin X. Reproductive outcomes of dual trigger with combination GnRH agonist and hCG versus trigger with hCG alone in women undergoing IVF/ICSI cycles: a retrospective cohort study with propensity score matching. BMC Pregnancy Childbirth. 2022: 583 [PMID: 35869444, https://doi.org/10.1186/s12884-022-04899-2]
47. Tu B, Zhang H, Chen L, Yang R, Liu P, Li R, Qiao J. Co-administration of GnRH-agonist and hCG (double trigger) for final oocyte maturation increases the number of top-quality embryos in patients undergoing IVF/ICSI cycles. J Ovarian Res. 2024: 137 [PMID: 38961417, https://doi.org/10.1186/s13048-024-01465-6]
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 ASIDE Health Sciences